SVRA vs. SLN, ZYME, LYEL, MLYS, PHAR, AVBP, ORIC, PHAT, STOK, and CALT
Should you be buying Savara stock or one of its competitors? The main competitors of Savara include Silence Therapeutics (SLN), Zymeworks (ZYME), Lyell Immunopharma (LYEL), Mineralys Therapeutics (MLYS), Pharming Group (PHAR), ArriVent BioPharma (AVBP), ORIC Pharmaceuticals (ORIC), Phathom Pharmaceuticals (PHAT), Stoke Therapeutics (STOK), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical preparations" industry.
Savara (NASDAQ:SVRA) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, community ranking, media sentiment, profitability, institutional ownership, risk, dividends and earnings.
In the previous week, Savara had 16 more articles in the media than Silence Therapeutics. MarketBeat recorded 21 mentions for Savara and 5 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.92 beat Savara's score of 0.01 indicating that Silence Therapeutics is being referred to more favorably in the news media.
Savara has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.
87.9% of Savara shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 4.6% of Savara shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Savara has a net margin of 0.00% compared to Silence Therapeutics' net margin of -171.41%. Savara's return on equity of -51.95% beat Silence Therapeutics' return on equity.
Silence Therapeutics has higher revenue and earnings than Savara. Silence Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.
Savara presently has a consensus target price of $8.80, suggesting a potential upside of 86.44%. Silence Therapeutics has a consensus target price of $57.25, suggesting a potential upside of 149.56%. Given Silence Therapeutics' higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than Savara.
Savara received 266 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Silence Therapeutics an outperform vote while only 65.98% of users gave Savara an outperform vote.
Summary
Savara beats Silence Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Savara News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
